Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Vaccines Global Market Report 2022
07:59am, Friday, 04'th Mar 2022 GlobeNewswire
Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co.
Emergent BioSolutions Inc. (NYSE:EBS) Is 24.62% Above Its 52-Week Low, But How Long Can It Continue?
03:30pm, Saturday, 26'th Feb 2022 Marketing Sentinel
In last trading session, Emergent BioSolutions Inc. (NYSE:EBS) saw 0.82 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $39.64 trading at -$2.7 or -6.38% at ring of the bell on the day assigns it a market valuation of $2.17B. That closing price of EBS’s stock is … Emergent BioSolutions Inc. (NYSE:EBS) Is 24.62% Above Its 52-Week Low, But How Long Can It Continue? Read More »
Emergent BioSolutions Inc. 2021 Q4 - Results - Earnings Call Presentation
09:48pm, Friday, 25'th Feb 2022 Seeking Alpha
Emergent BioSolutions Stock Fell Today -- Is It a Buy?
09:31pm, Friday, 25'th Feb 2022 The Motley Fool
There's considerable uncertainty about the company's near-term prospects.
Emergent BioSolutions Stock Fell Today -- Is It a Buy?
09:31pm, Friday, 25'th Feb 2022 The Motley Fool
There''s considerable uncertainty about the company''s near-term prospects.
Emergent BioSolutions to begin ''improvements'' at Baltimore facility as J&J evaluates Covid vaccine demand
05:48pm, Friday, 25'th Feb 2022 Business Journals
The company has also made some changes to its leadership team.
Why Emergent BioSciences Stock Is Slipping Today
04:58pm, Friday, 25'th Feb 2022 The Motley Fool
The company disappointed investors with its 2022 guidance.
Emergent BioSolutions Stock Fell Today -- Is It a Buy?
04:31pm, Friday, 25'th Feb 2022
There's considerable uncertainty about the company's near-term prospects.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
04:05pm, Friday, 25'th Feb 2022 Zacks Investment Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
12:16pm, Friday, 25'th Feb 2022
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Why Emergent BioSciences Stock Is Slipping Today
11:58am, Friday, 25'th Feb 2022
The company disappointed investors with its 2022 guidance.
Emergent BioSolutions (EBS) Q4 2021 Earnings Call Transcript
04:00am, Friday, 25'th Feb 2022 The Motley Fool
EBS earnings call for the period ending December 31, 2021.
Emergent BioSolutions (EBS) Q4 2021 Earnings Call Transcript
04:00am, Friday, 25'th Feb 2022 The Motley Fool
EBS earnings call for the period ending December 31, 2021.
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript
03:04am, Friday, 25'th Feb 2022 Seeking AlphaEmergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript
10:04pm, Thursday, 24'th Feb 2022
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript
